Dolatrai Vyas - Spectrum Pharmaceuticals Independent Director
| SPPIDelisted Stock | USD 1.03 0.00 0.00% |
Director
Dr. Dolatrai Vyas, Ph.D. is an Independent Director of Spectrum Pharmaceuticals Inc. Dr. Vyas has 31 years of tenure in oncology drug discovery research at BristolMyers Squibb Company, a pharmaceutical company, where he served in various positions, including most recently as a Group Director and Distinguished Research Fellow in Oncology Discovery Chemistry since 2013.
| Age | 74 |
| Tenure | 11 years |
| Phone | 617 586 3900 |
| Web | https://www.sppirx.com |
Dolatrai Vyas Latest Insider Activity
Tracking and analyzing the buying and selling activities of Dolatrai Vyas against Spectrum Pharmaceuticals stock is an integral part of due diligence when investing in Spectrum Pharmaceuticals. Dolatrai Vyas insider activity provides valuable insight into whether Spectrum Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Spectrum Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Spectrum Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Dolatrai Vyas over six months ago Acquisition by Dolatrai Vyas of 20000 shares of Spectrum Pharmaceuticals subject to Rule 16b-3 |
Spectrum Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3821) % which means that it has lost $0.3821 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6502) %, meaning that it created substantial loss on money invested by shareholders. Spectrum Pharmaceuticals' management efficiency ratios could be used to measure how well Spectrum Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 29.43 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. Spectrum Pharmaceuticals has a current ratio of 1.75, which is within standard range for the sector. Debt can assist Spectrum Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Spectrum Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Spectrum Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Spectrum to invest in growth at high rates of return. When we think about Spectrum Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Bryan Lawlis | Geron | 66 | |
| Arnold Lippa | Hepion Pharmaceuticals | 70 | |
| Eric Rowinsky | Verastem | 61 | |
| Geoffrey Block | Ardelyx | N/A | |
| Daniel Bradbury | Geron | 56 | |
| John Agwunobi | Bluebird bio | 53 | |
| Robert Nelsen | Agios Pharm | 51 | |
| Meryl Zausner | Seres Therapeutics | 61 | |
| Louise Phanstiel | Verastem | 58 | |
| Scott Garland | Karyopharm Therapeutics | 49 | |
| Henri Termeer | Verastem | 67 | |
| Doug Cole | Agios Pharm | 54 | |
| Michael Kauffman | Verastem | 54 | |
| Someit MD | Zura Bio Limited | 34 | |
| Robert Lefkowitz | Lexicon Pharmaceuticals | 74 | |
| Richard Rodgers | Ardelyx | 49 | |
| Mansoor Mirza | Karyopharm Therapeutics | 57 | |
| John Brancaccio | Hepion Pharmaceuticals | 69 | |
| Richard Kender | Seres Therapeutics | 62 | |
| Robert Spiegel | Geron | 68 | |
| Karin Eastham | Geron | 67 | |
Management Performance
| Return On Equity | -1.65 | |||
| Return On Asset | -0.38 |
Spectrum Pharmaceuticals Leadership Team
Elected by the shareholders, the Spectrum Pharmaceuticals' board of directors comprises two types of representatives: Spectrum Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Spectrum. The board's role is to monitor Spectrum Pharmaceuticals' management team and ensure that shareholders' interests are well served. Spectrum Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Spectrum Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stuart Krassner, Independent Director | ||
| Raymond Cohen, Independent Director | ||
| Michael Grabow, Exec Officer | ||
| Nora Brennan, Ex Officer | ||
| Joseph Turgeon, Pres and COO | ||
| Dolatrai Vyas, Independent Director | ||
| Keith McGahan, Senior Vice President Chief Legal Officer and Corporate Secretary | ||
| LLM JD, Chief VP | ||
| MD MBA, VP Devel | ||
| Jeffrey Vacirca, Director | ||
| William Ashton, Independent Director | ||
| Luigi Lenaz, Director | ||
| Gilles Gagnon, Director | ||
| Bimal Shah, VP Devel | ||
| Kurt Gustafson, CFO, Principal Accounting Officer and Executive VP | ||
| Rajesh Shrotriya, Chairman of the Board, CEO | ||
| Elizabeth Czerepak, Director | ||
| Bernice Welles, Independent Director | ||
| Thomas Riga, CEO Pres | ||
| Anthony Maida, Independent Director | ||
| MD FRCPC, Ex Officer |
Spectrum Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Spectrum Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.65 | |||
| Return On Asset | -0.38 | |||
| Profit Margin | (2.52) % | |||
| Operating Margin | (2.47) % | |||
| Current Valuation | 185.27 M | |||
| Shares Outstanding | 205.25 M | |||
| Shares Owned By Insiders | 11.00 % | |||
| Shares Owned By Institutions | 22.93 % | |||
| Number Of Shares Shorted | 3.33 M | |||
| Price To Earning | (19.44) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Spectrum Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Spectrum Pharmaceuticals' short interest history, or implied volatility extrapolated from Spectrum Pharmaceuticals options trading.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Spectrum Stock
If you are still planning to invest in Spectrum Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Spectrum Pharmaceuticals' history and understand the potential risks before investing.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |